What it's for (Indications)
- Tamsulosin HCl + Dutasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate.
- This fixed-dose combination addresses both the dynamic and static components of BPH.
- Tamsulosin, an alpha-1A adrenergic receptor antagonist, provides rapid symptom relief by relaxing smooth muscle in the prostate and bladder neck, thereby improving urine flow.
- Dutasteride, a dual 5-alpha-reductase inhibitor, works by reducing prostate size, preventing BPH progression, and reducing the risk of acute urinary retention (AUR) and the need for BPH-related surgery.
- The combination therapy is typically considered for patients who have not adequately responded to monotherapy with either agent or for those with more severe symptoms and a significantly enlarged prostate.
- It is crucial to confirm the diagnosis of BPH and exclude other serious urological conditions, such as prostate cancer, before initiating treatment.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage for Tamsulosin HCl + Dutasteride is one capsule (0.4 mg tamsulosin HCl and 0.5 mg dutasteride) taken orally once daily, approximately 30 minutes after the same meal each day. Swallowing the capsule whole is essential; it should not be chewed or opened, as contact with the capsule contents may result in oropharyngeal irritation. The full therapeutic benefits of dutasteride in reducing prostate size may take several months to manifest, while tamsulosin typically provides symptom relief within weeks. Dosage adjustments for renal impairment are generally not required. However, caution should be exercised in patients with severe hepatic impairment, and the drug is contraindicated in such cases as dutasteride is extensively metabolized in the liver. Adherence to the prescribed regimen is important for achieving and maintaining therapeutic efficacy and reducing symptom burden associated with BPH. |
Safety & Warnings
Common Side Effects
- Common side effects associated with Tamsulosin HCl + Dutasteride combination therapy often reflect the individual pharmacological actions of its components.
- Tamsulosin-related adverse events include dizziness, orthostatic hypotension (especially upon standing), abnormal ejaculation (including retrograde ejaculation and anejaculation), rhinitis, and headache.
- Dutasteride-related side effects primarily involve sexual dysfunction, such as decreased libido, erectile dysfunction, and ejaculation disorders, which may persist even after treatment discontinuation in some cases.
- Gynecomastia (breast enlargement and tenderness) and breast pain have also been reported with dutasteride.
- Other less common but potentially serious side effects include allergic reactions (rash, pruritus, urticaria, localized edema), syncope, and, very rarely, priapism.
- Patients should be counselled on these potential side effects and advised to report any persistent or severe adverse reactions to their healthcare provider.
- The combination may intensify the incidence of sexual dysfunction observed with dutasteride monotherapy.
Serious Warnings
- Black Box Warning: Tamsulosin HCl + Dutasteride does not carry a specific FDA-mandated Black Box Warning. However, several serious warnings and precautions are paramount for safe and effective use. These 'Serious Warnings' include the risk of orthostatic hypotension and syncope, particularly at the initiation of tamsulosin treatment or dose escalation, requiring patient counseling on changing positions slowly. Dutasteride can significantly decrease serum prostate-specific antigen (PSA) levels, which may mask the detection of prostate cancer. Healthcare providers must establish a new PSA baseline and carefully interpret PSA values during treatment, evaluating any sustained increase from the nadir PSA level for potential prostate cancer. There is also a rare but increased risk of high-grade prostate cancer reported in some studies with 5-alpha-reductase inhibitors. Furthermore, dutasteride is teratogenic and poses a significant risk to a male fetus, necessitating that pregnant women or women of childbearing potential avoid any contact with the drug. Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in patients treated with alpha-1 blockers like tamsulosin, requiring ophthalmologists to be aware of the patient's medication history. Rarely, male breast cancer has been reported with 5-alpha-reductase inhibitors, requiring prompt evaluation of any breast changes. Patients with severe hepatic impairment should avoid this medication due to the extensive metabolism of dutasteride in the liver. These warnings underscore the need for careful patient selection, comprehensive patient education, and vigilant monitoring throughout the course of therapy.
- Several important warnings must be considered with Tamsulosin HCl + Dutasteride.
- Orthostatic hypotension, characterized by dizziness, lightheadedness, or syncope, particularly when standing up quickly, can occur due to tamsulosin's alpha-adrenergic blocking effects.
- Patients should be cautioned about these potential effects, especially when initiating therapy or increasing dosage.
- Dutasteride can affect prostate-specific antigen (PSA) levels, reducing them by approximately 50% after 6 months of treatment, which can mask the detection of prostate cancer.
- Therefore, a new PSA baseline should be established after 3-6 months of treatment, and any sustained increase from the lowest PSA level while on treatment should be carefully evaluated for potential prostate cancer, even if values are within the normal range.
- Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract surgery in some patients treated with alpha-1 blockers like tamsulosin, necessitating ophthalmologist awareness.
- Exposure to dutasteride, even through skin contact or ingestion by pregnant women, poses a significant risk to a male fetus due to its anti-androgenic effects, potentially causing external genital abnormalities; therefore, pregnant women or women of childbearing potential should not handle leaking capsules.
- Dutasteride has also been associated with an increased risk of high-grade prostate cancer in some studies and male breast cancer, although rare.
- Patients should be monitored for any breast changes, such as lumps, pain, or nipple discharge.
- Caution is advised in patients with severe hepatic impairment, as dutasteride is extensively metabolized by the liver.
- Patients with a history of sulfa allergy should be cautiously monitored due to tamsulosin's sulfonamide moiety.
- These warnings highlight the necessity for careful patient selection, monitoring, and comprehensive patient education.
How it Works (Mechanism of Action)
The therapeutic efficacy of Tamsulosin HCl + Dutasteride arises from the synergistic actions of its two components. Tamsulosin is a selective antagonist of alpha-1A adrenergic receptors, which are predominantly located in the smooth muscle of the prostate, prostatic capsule, bladder neck, and prostatic urethra. By selectively blocking these receptors, tamsulosin induces relaxation of the smooth muscle tissue, thereby reducing dynamic obstruction to urine flow and alleviating irritative and obstructive voiding symptoms associated with BPH, such as frequency, urgency, nocturia, and weak stream. Its selectivity minimizes effects on vascular alpha-1B receptors, potentially reducing systemic hypotensive effects compared to non-selective alpha-blockers. Dutasteride is a potent, dual inhibitor of both type 1 and type 2 5-alpha-reductase isoenzymes. These enzymes are responsible for converting testosterone into dihydrotestosterone (DHT), a potent androgen essential for the development and growth of the prostate gland. By inhibiting DHT production, dutasteride effectively reduces the size of the enlarged prostate over time, thereby reducing the static component of obstruction. This reduction in prostate volume helps to improve urinary flow, decrease the risk of acute urinary retention, and lessen the need for surgical intervention in men with BPH. The combination addresses both rapid symptom relief and long-term prostate volume reduction.
Commercial Brands (Alternatives)
No other brands found for this formula.